Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

February 27, 2023

Study Completion Date

February 27, 2023

Conditions

Tuberculosis

Interventions

DRUG

TBAJ-587

oral suspension

DRUG

Placebo

matching placebo oral suspension for TBAJ-587

Trial Locations (1)

QPS Netherlands B.V., Groningen

All Listed Sponsors

collaborator

QPS Holdings LLC

INDUSTRY

lead

Global Alliance for TB Drug Development

OTHER

NCT04890535 - Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults | Biotech Hunter | Biotech Hunter